Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Colin D. Marchant"'
Autor:
Kristina A. Bryant, Jodie McVernon, Colin D. Marchant, Terry Nolan, Gary S. Marshall, Peter Richmond, Helen Marshall, Michael Nissen, Stephen B. Lambert, Emmanuel Aris, Narcisa Mesaros, Jacqueline M. Miller
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 8, Iss 8, Pp 1036-1041 (2012)
A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjuga
Externí odkaz:
https://doaj.org/article/8bd8ef9ce14444d7ac144b61f5f55d3d
Autor:
Kathleen Jakob, Meyer Kattan, Paige Lewis, Colin D. Marchant, Elizabeth D. Barnett, Angela Barrett, Nadira Fernandez, Karen R. Broder, Philip LaRussa, Devindra Sharma, A. Patrica Wodi, Anne Marie Rezendes, Melissa S. Stockwell
Background Using text messaging for vaccine safety monitoring, particularly for non-medically attended events, would be valuable for pandemic influenza and emergency vaccination program preparedness. We assessed the feasibility and acceptability of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d1069c6e1133b1bc5007a6dcea3477
https://europepmc.org/articles/PMC6693331/
https://europepmc.org/articles/PMC6693331/
Autor:
Jacqueline M. Miller, Colin D. Marchant, Gary S. Marshall, Emmanuel Aris, Narcisa Mesaros, Mark M. Blatter
Publikováno v:
Pediatric Infectious Disease Journal. 32:662-668
A 4-dose series of recently licensed Haemophilus influenzae type b-meningococcal serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) was immunogenic with a clinically acceptable safety profile in infants, with antibodies persisting in m
Autor:
Roger Baxter, Claudia Vellozzi, Neal A. Halsey, Ali Rowhani-Rahbar, Nicola P. Klein, Cornelia L. Dekker, Bruce Fireman, Colin D. Marchant, Kathryn M. Edwards, James J. Sejvar
Publikováno v:
Vaccine. 31:271-277
In immunization safety research, individuals are considered at risk for the development of certain adverse events following immunization (AEFI) within a specific period of time referred to as the risk interval. These intervals should ideally be deter
Autor:
David P. Greenberg, Colin D. Marchant, Carl Heinz Wirsing von König, Stanley A. Plotkin, Tina Tan, David R. Johnson, James D. Cherry, Usa Thisyakorn, Kevin D. Forsyth
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Existing clinical case definitions of pertussis are decades old and based largely on clinical presentation in infants and children, yet an increasing burden is borne by adolescents and adults who may manifest distinct signs/symptoms. Therefore, a "on
Autor:
Michael D. Nissen, Jodie McVernon, Gary S. Marshall, Stephen B. Lambert, Emmanuel Aris, Colin D. Marchant, Peter Richmond, Jacqueline M. Miller, Kristina A. Bryant, Narcisa Mesaros, Helen Marshall, Terry Nolan
Publikováno v:
Human Vaccines & Immunotherapeutics
A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjuga
Autor:
Terry Nolan, Emmanuel Aris, Dominique Boutriau, Pascal Lestrate, Noris Pavia-Ruiz, Mark M. Blatter, Colin D. Marchant, Kristina A. Bryant, Gary S. Marshall, Leonard R. Friedland, Jacqueline M. Miller, Stephen Rinderknecht
Publikováno v:
Pediatrics. 127:e1375-e1385
BACKGROUND: Meningococcal disease incidence is highest in children younger than 2 years of age, yet there is no US-licensed vaccine for this age group. A phase III study evaluated the immunogenicity and safety of an investigational Haemophilus influe
Autor:
Cornelia L. Dekker, Roger Baxter, Jennifer Kissner, Colin D. Marchant, Kathryn M. Edwards, Neal A. Halsey, Philip LaRussa, Nicola P. Klein, Renata J.M. Engler, Barbara A. Slade
Publikováno v:
Pediatrics. 127:S65-S73
The Clinical Immunization Safety Assessment (CISA) Network is a collaboration between the Centers for Disease Control and Prevention (CDC) and 6 academic medical centers to provide support for immunization safety assessment and research. The CISA Net
Autor:
Robert Sparks, Diane B. Fawkes, Colin D. Marchant, Chelsea Cupp, Sallee Taylor, Kathryn M. Edwards, Virginia Frontiero, Anne Marie Rezendes, Stacy Dorris, Dana C. Crawford, Logan Dumitrescu, E. Kathryn Miller
Publikováno v:
Vaccine. 29:3431-3437
A large multinational clinical trial compared the safety and efficacy of intranasal trivalent live attenuated influenza vaccine (LAIV) with intramuscular trivalent inactivated vaccine (TIV) in children 6 to 59 months of age prior to the 2004–05 inf
Autor:
Melissa Catlett, Heather L. Sings, Michelle Collins-Ogle, Richard M. Haupt, Stan L. Block, Keith S. Reisinger, Colin D. Marchant, David Radley, Elizabeth I.O. Garner
Publikováno v:
Pediatrics. 125:1142-1151
OBJECTIVES: Multinational phase III trials of a human papillomavirus vaccine, Gardasil, have shown the vaccine to be generally well-tolerated, efficacious, and immunogenic. We evaluated the immunogenicity and safety of Gardasil administered concomita